Literature DB >> 22892758

Nuclear factor κB activity correlates with the progression and prognosis of pancreatic cancer in a mouse model.

Kenei Furukawa1, Tadashi Uwagawa, Koichiro Haruki, Yuki Fujiwara, Tomonori Iida, Hiroaki Shiba, Takeyuki Misawa, Toya Ohashi, Katsuhiko Yanaga.   

Abstract

INTRODUCTION: Constitutive NF-κB activation is considered to play a key role in the aggressive behavior of pancreatic cancer. Although NF-κB in tumors may contribute to aggressive characteristic features via transcription of angiogenesis and invasion-related factors, there is no definitive evidence showing a correlation between quantitated NF-κB activity and prognosis. In this study, we quantitated NF-κB activity of various human pancreatic cancer cell lines and evaluated whether NF-κB activity was related to tumor progression and prognosis for pancreatic cancer in mice.
MATERIALS AND METHODS: We quantitated NF-κB activity in six pancreatic cancer cell lines (AsPC-1, BxPC-3, Capan-2, MIAPaCa-2, Panc-1 and PL45) and evaluated downstream target genes of NF-κB such as VEGF, IL-8 and MMP-9 in vitro. Next, we evaluated tumor progression and prognosis using subcutaneous tumor model in vivo between cell lines with the highest and lowest NF-κB activity.
RESULTS: BxPC-3 had the highest and AsPC-1 had the lowest NF-κB activity in the 6 cell lines. Expression of VEGF, IL-8 and MMP-9 in BxPC-3 was significantly higher than those in AsPC-1 cells in vitro (p < 0.001) and tumor growth in BxPC-3 was faster than that in AsPC-1 group (p < 0.001) resulting in worse survival in vivo (p = 0.0339).
CONCLUSION: These results suggested that NF-κB activity is related to expression of its downstream target genes, tumor progression and prognosis in experimental pancreatic cancer model.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22892758     DOI: 10.1007/s00595-012-0279-5

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  34 in total

Review 1.  New insights into the role of nuclear factor-kappaB in cell growth regulation.

Authors:  F Chen; V Castranova; X Shi
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

2.  Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.

Authors:  Alexander Arlt; Andre Gehrz; Susanne Müerköster; Jens Vorndamm; Marie-Luise Kruse; Ulrich R Fölsch; Heiner Schäfer
Journal:  Oncogene       Date:  2003-05-22       Impact factor: 9.867

3.  Suppression of TNF-alpha-induced apoptosis by NF-kappaB.

Authors:  D J Van Antwerp; S J Martin; T Kafri; D R Green; I M Verma
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

4.  Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer.

Authors:  Yuichi Nagakawa; Tatsuya Aoki; Kazuhiko Kasuya; Akihiko Tsuchida; Yasuhisa Koyanagi
Journal:  Pancreas       Date:  2002-03       Impact factor: 3.327

5.  Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

Authors:  Jordan D Berlin; Paul Catalano; James P Thomas; John W Kugler; Daniel G Haller; Al Bowen Benson
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

6.  A protocol for immunoaffinity separation of the accumulated ubiquitin-protein conjugates solubilized with sodium dodecyl sulfate.

Authors:  Yohta Shimada; Takahiro Fukuda; Katsuhiko Aoki; Toyokazu Yukawa; Shawichi Iwamuro; Kiyoshi Ohkawa; Koji Takada
Journal:  Anal Biochem       Date:  2008-03-04       Impact factor: 3.365

7.  Phase II trial of curcumin in patients with advanced pancreatic cancer.

Authors:  Navneet Dhillon; Bharat B Aggarwal; Robert A Newman; Robert A Wolff; Ajaikumar B Kunnumakkara; James L Abbruzzese; Chaan S Ng; Vladimir Badmaev; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

8.  Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients.

Authors:  Jonathan E Lim; Michael W Chien; Craig C Earle
Journal:  Ann Surg       Date:  2003-01       Impact factor: 12.969

9.  The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.

Authors:  W Wang; J L Abbruzzese; D B Evans; L Larry; K R Cleary; P J Chiao
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

10.  Association of p53 gene mutations with short survival in pancreatic adenocarcinoma.

Authors:  S Nakamori; K Yashima; Y Murakami; O Ishikawa; H Ohigashi; S Imaoka; S Yaegashi; Y Konishi; T Sekiya
Journal:  Jpn J Cancer Res       Date:  1995-02
View more
  9 in total

1.  Poor prognosis of common-type invasive ductal carcinomas that originate in the branching pancreatic duct.

Authors:  Masataka Ando; Yasuhiro Shimizu; Tsuyoshi Sano; Yoshiki Senda; Yuji Nimura; Kenji Yamao; Masato Nagino; Akio Yanagisawa
Journal:  Surg Today       Date:  2014-12-05       Impact factor: 2.549

Review 2.  Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer.

Authors:  Tadashi Uwagawa; Katsuhiko Yanaga
Journal:  Surg Today       Date:  2015-02-12       Impact factor: 2.549

3.  Impact of Osteopenia on Oncologic Outcomes After Curative Resection for Pancreatic Cancer.

Authors:  Takashi Motomura; Hideaki Uchiyama; Tomohiro Iguchi; Mizuki Ninomiya; Rintaro Yoshida; Takuya Honboh; Noriaki Sadanaga; Tetsuro Akashi; Hiroshi Matsuura
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

4.  The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms.

Authors:  Khanh Vinh Quốc Lu'o'ng; Lan Thi Hoàng Nguyễn
Journal:  Cancer Manag Res       Date:  2012-12-18       Impact factor: 3.989

5.  Nectin expression in pancreatic adenocarcinoma: nectin-3 is associated with a poor prognosis.

Authors:  Hideki Izumi; Kenichi Hirabayashi; Naoya Nakamura; Toshio Nakagohri
Journal:  Surg Today       Date:  2015-02-19       Impact factor: 2.549

Review 6.  NF-κB Dependent Chemokine Signaling in Pancreatic Cancer.

Authors:  Claudia Geismann; Heiner Schäfer; Jan-Paul Gundlach; Charlotte Hauser; Jan-Hendrik Egberts; Günter Schneider; Alexander Arlt
Journal:  Cancers (Basel)       Date:  2019-09-26       Impact factor: 6.639

Review 7.  Prognostic value of preoperative low bone mineral density in patients with digestive cancers: a systematic review and meta-analysis.

Authors:  Jun Watanabe; Akihiro Saitsu; Atsushi Miki; Kazuhiko Kotani; Naohiro Sata
Journal:  Arch Osteoporos       Date:  2022-02-11       Impact factor: 2.617

8.  Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo.

Authors:  Nobuhiro Saito; Yoshihiro Shirai; Tadashi Uwagawa; Takashi Horiuchi; Hiroshi Sugano; Koichiro Haruki; Hiroaki Shiba; Toya Ohashi; Katsuhiko Yanaga
Journal:  Oncotarget       Date:  2018-03-02

9.  MicroRNA-200c affects bladder cancer angiogenesis by regulating the Akt2/mTOR/HIF-1 axis.

Authors:  Shui-Qing Wu; Hai-Qing He; Ye Kang; Ran Xu; Lei Zhang; Xiao-Kun Zhao; Xuan Zhu
Journal:  Transl Cancer Res       Date:  2019-12       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.